# Melanotan 2 vs PT-141: Comparing the Research

> Melanotan 2 vs PT-141 (bremelanotide): same scaffold, different fate. The receptor selectivity, approval status, and sexual-function evidence compared and cited.

One scaffold, two destinations — a non-selective tanning-and-sex peptide versus a sexual-function drug that reached approval.

## The short version

Melanotan 2 vs PT-141 is a story of one molecule and its more focused descendant. Melanotan 2 came first: a ring-shaped melanocortin peptide that hits all five receptors, so it tans skin, curbs appetite, and triggers erections all at once. PT-141 (its generic name is bremelanotide) was engineered from the Melanotan 2 scaffold to lean toward the MC4R receptor — the one tied to sexual response — and away from the pigment receptor.

The practical difference is approval. PT-141 completed large trials and is approved for one sexual-desire condition in premenopausal women [7][13]. Melanotan 2 was never approved for anything; its human data stop at small Phase I studies [3]. They are relatives, not interchangeable — and PT-141's approval and safety data do not transfer to Melanotan 2.

## Same scaffold, different selectivity

Both peptides descend from alpha-MSH and both act on the melanocortin receptors, but their selectivity differs. Melanotan 2 is non-selective across MC1R-MC5R [3], which is precisely why it darkens skin (MC1R) at the same time it affects appetite and erections (MC4R/MC3R). PT-141 was developed from the Melanotan 2 structure with the explicit goal of MC4R-weighted sexual activity and reduced pigmentation activity [13].

That single design choice explains most of the contrast. A peptide that drives pigment will tan and will darken moles; a peptide tuned away from MC1R does less of that. The sexual mechanism they share is central — melanocortin signaling in the brain, documented for Melanotan 2 in human and animal studies [2][10] and for the broader class in the functional-MRI work in women [7].

## The evidence and approval status compared

On evidence, the two diverge sharply. Melanotan 2's controlled human data are the 1996 pigmentation pilot (n=3) and the 1998 erectile-dysfunction crossover (n=10, 8 of 10 responders, 38.0 vs 3.0 minutes of rigidity) [1][2] — striking but small, with no completed Phase II or III [3]. PT-141 advanced through the melanocortin-sexual-dysfunction development program toward pivotal trials and commercialization [3][13], and MC4R agonism was shown in a randomized functional-MRI study to enhance sexual brain processing and desire in women with hypoactive sexual desire disorder [7].

On status: PT-141 holds a regulatory approval for sexual dysfunction; Melanotan 2 holds none anywhere [3][29]. This matters for safety too. PT-141's approval rests on controlled-trial safety data in its specific indication. Melanotan 2's safety record is built from case reports — renal infarction [4], priapism [25][26][27], and changing moles or melanoma [16][21] — in people using unregulated product without oversight. The approval and trial-safety data for the derivative do not extend to Melanotan 2 [13][3].

## Field reports on the comparison

Community discussion often frames the two as a trade-off — Melanotan 2 'tans and does the sexual thing,' PT-141 'just does the sexual thing.' That folk summary roughly tracks the selectivity difference, but it is reported experience, not evidence, and it routinely omits the melanocyte risk that comes with Melanotan 2's MC1R activity [33][34]. It also cannot account for what is actually in an unverified vial [22]. Read the comparison from the receptor pharmacology and the trial data above, not from the trade-off slogan.

---

A charcoal instrument-cluster reading of the Melanotan 2 record — the sexual-function trials logged first, the half-life and receptor data stated as plain gauge values, the priapism, kidney and changing-mole case reports flagged in plain sight; no clinic behind the console and nothing here dosed, injected, prescribed, or sold.